Search Results
KRAS G12C Inhibition in Advanced NSCLC: AMG 510
KRAS G12C Inhibition in Advanced NSCLC: AMG 510
AMG 510 KRAS Inhibitor trial results – ‘A good start’ | Colin Lindsay
Key lung cancer updates: KRAS(G12C) inhibitors and ADCs
KRAS G12C Inhibition in Advanced NSCLC: MRTX849
KRAS G12C Inhibition in Advanced NSCLC: MRTX849
Dr. Fakih on the Safety Profile of AMG 510 in KRAS G12C-Mutated CRC
ESMO highlights: KRAS G12C inhibitors
Practical Considerations for AMG 510 in KRAS-Mutant NSCLC
KRAS G12C Inhibitors: Acquired Resistance and Combo Strategies
AMG 510: A novel molecule targeting KRAS G12C mutatant solid tumours
Govindan Discusses the Phase I Results of AMG 510 Evaluated in NSCLC
